Wall Street braced for results from retail giants as rising concerns over inflation cloud the path to an interest rate cut.

(Reuters) -Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ever-growing popularity of Eli Lilly's Zepbound and Novo Nordisk's ...

Viking Therapeutics' stock was crushed after a mid-stage trial of its oral weight-loss drug. Viking Therapeutics Inc. on Tuesday announced that a trial showed its oral weight-loss drug works - and ...

(Reuters) -Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks ...

Viking Therapeutics Inc. plunged in early trading on Tuesday after its experimental obesity pill disappointed in a mid-stage ...

A doctor has explained how the body adjusts to the weight-loss drug Mounjaro during its first month of use. Weight loss drugs ...

Discover how weight-loss drugs like Wegovy and Mounjaro are being tested for a range of health conditions including alcohol addiction, Alzheimer's disease, and cardiovascular issues. Learn about their ...

Discover how rising healthcare spending can be turned into income growth. Build a retirement portfolio that thrives in a key ...

Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ...

Andersen has a fair value estimate of $71 for Novo stock. Closing around $52.41 on Aug. 15 (near its lowest level since ...

The deal allows Eli Lilly and Company (NYSE:LLY) to have exclusive rights to develop and commercialize drug candidates ...

Novo Nordisk announced Monday that U.S. patients can now get a month's supply of Ozempic, the blockbuster diabetes drug, for ...